Skip to main content
Premium Trial:

Request an Annual Quote

K. Michael Forrest, Raymond Ruddon, Michael Buchmeier, V.W. Brinkerhoff III, and Margaret Liu

Premium

AVI BioPharma said this week that it has appointed K. Michael Forrest to its board of directors. Forrest, who is filling the unexpired term of former director Raymond Ruddon, will serve until 2006. Rudden is transitioning to the company’s scientific advisory board.

Forrest was previously CEO of Cellegy Pharmaceuticals. Prior to this, he served in various positions at American Cyanimid and Pfizer.

AVI also announced that Michael Buchmeier, a professor at The Scripps Research Institute, has joined the company’s SAB.


V.W. Brinkerhoff III has been appointed senior vice president and general manager for Gene Logic’s preclinical contract research business, the company said this week.

Prior to joining Gene Logic, Brinkerhoff served in senior management positions at Life Technologies, now Invitrogen.


Sangamo Biosciences said this week that it has appointed Margaret Liu to its board of directors.

Liu has served as senior director at Merck Research Laboratories in the department of virus and cell biology, vice president of vaccines research and gene therapy at Chiron, and senior advisor in vaccinology at the Bill and Melinda Gates Foundation.

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.